MicroRNA profiles in blood and urine in lung cancer: a pilot study

Completed

Conditions: lungcancer
10038666

Registration Number: NL-OMON46585

Lead Sponsor: niversiteit Twente

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

maximal 75 patients with a suspicion of lung cancer (in order to obtain 25 patients with lungcancer stage 3 / 4 and 25 patients with a negative diagnosis)
- between 45-80 years of age

Exclusion Criteria

Patients; known other than lung cancer malignity, urinary tract infection
Controls: known other than lung cancer malignity, no suspicion of lung cancer malignicy, pneumonia, urinary tract infection

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are microRNA sequencing data (read-counts per<br /><br>microRNA) derived from next generation<br /><br>sequencing of the small RNA fractions of blood and urine. The sequencing data<br /><br>will be correlated to clinical parameters:<br /><br>diagnosed with lung cancer (CT, histopathology), suspected of having lung<br /><br>cancer but not diagnosed (CT, possibly histopathology),<br /><br>not-suspected of lung cancer or any other disease. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Measurements of volatile organic compounds (VOCs) resulting from the electronic<br /><br>nose technology. With the primary outcomes and the secondary outcomes a<br /><br>predictive model will be developed to predict the probability for having lung<br /><br>cancer. </p><br>